MEET QPS AT AD/PD™ 2024; March 5-9, Lisbon, Portugal
Newsletter

QPS Austria now offers the Tau transgenic PS19 mouse for your research!

QPS Neuropharmacology

QPS Austria now licensed the PS19 transgenic mouse from the University of Pennsylvania, USA (JAX 008169; Yoshiyama et al., 2007). The mouse expresses the T34 isoform and 4 microtubule binding repeats (1N4R) of the tau protein with P301S mutation under the regulatory control of the murine prion promoter (Prnp). PS19 mice are a popular model to study tau aggregation, tauopathy and other symptoms of Alzheimer`s disease.

mouse

Animals present the following phenotype:

  • Neuronal accumulation of phosphorylated tau and paired helical filaments (PHF) in different brain regions at 6 months (Yoshiyama et al., 2007)
  • Cerebral atrophy and neuron loss at 12 months (Yoshiyama et al., 2007)
  • Neuroinflammation observed as activated microglia and astrocytosis at 6 months and older (Yoshiyama et al., 2007; Lopez-Gonzalez et al., 2015)
  • Muscle weakness and neurogenic muscular atrophy at 3 months (Yoshiyama et al., 2007)
  • Reduced anxiety at 9 months (Briggs et al., 2017)
  • Learning and memory deficits at 9 months (Briggs et al., 2017)
  • Reduced survival (Yoshiyama et al., 2007)

Results from published efficacy studies show that many of these symptoms are partly reversible by different compounds:

  • Survival, nueroinflammation, tau phosphorylation (Yoshiyama et al., 2007)
  • Axonal dystrophy, learning and memory (Brunden et al., 2010)
  • Brain atrophy, survival, nest building (DeVos et al., 2017)

The phenotype described above, relevant for AD and other neurodegenerative disorders, makes the PS19 mouse a perfect model for your drug testing.

Just released: QPS Austria`s latest scientific publication about the Niemann-Pick type 1 mouse model NPC1-/-

Hepatic and neuronal phenotype of NPC1−/− mice


March 26-31 2019

Meet us at the 14th International Conference on Alzheimer´s & Parkinson´s Diseases in Lisbon, Portugal

The clinical and neuropharmacology teams of QPS will attend the AD/PD 2019 and are pleased to meet you at our booth # 28.

Additionally, our scientists are presenting our newest research results in oral and poster presentations:

Oral Presentation:

Wednesday, March 27th, 12:30H:

CHARACTERIZATION OF 4L/PS-NA MICE FOR ENZYME ACTIVITY, SUBSTRATE CONCENTRATIONS AS WELL AS INFLAMMATION TO MODEL GAUCHER DISEASE

Irene Schilcher, Ewald Auer, Victoria Schiffer, Tina Loeffler, Joerg Neddens, Staffan Schmidt, Jan Kehr, Birgit Hutter-Paier

Poster plus 5 minute talks:

Saturday, March 30th:

09:20H: # 395: TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE

Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier

10:00H: # 399: UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS

Magdalena Temmel, Meritxell Aguilo Garcia, Tina Loeffler, Joerg Neddens, Irati Aiestaran Zelaia, Vera Niederkofler, Stefanie Flunkert and Birgit Hutter-Paier

Poster:

# 348: INVESTIGATION OF SKIN SAMPLES OF ALPHA-SYNUCLEIN TRANSGENIC MICE LINE 61, D-LINE AND A53T

Joerg Neddens, Estibaliz Etxebarria, Victoria Krivitsch, Birgit Hutter-Paier

# 398: PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE

Magdalena Temmel, Tina Loeffler, Joerg Neddens, Irene Schilcher, Birgit Hutter-Paier

# 390: CONSTRUCTION OF A TAU-SEED INJECTION MODEL USING HTAU MICE

Shigeru Akasofu, Jane Gartlon, Malcolm Roberts, Ezat Sajedi, Rohan de Silva, Tina Loeffler, Birgit Hutter-Paier

# 707: BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS BACHD RATS

Tina Loeffler, Stephan Kurat, Adam Horvath, Stefanie Flunkert, Hoa Huu Phuc Nguyen, Robert Wronski, Birgit Hutter-Paier

Request a meeting

Subscribe to our Newsletter

Name
Address
Confirmation*
This field is for validation purposes and should be left unchanged.

Newsletter